These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38644565)

  • 1. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
    Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
    CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
    Wang Q; Niu W; Pan H
    Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.
    Lai S; Li P; Liu X; Liu G; Xie T; Zhang X; Wang X; Huang J; Tang Y; Liu Z; Shen G; Li C; Lu F; Wang L; Jiang F; Sun C; Chen Y; Chen M
    Cancer Biol Med; 2024 Mar; 21(5):433-44. PubMed ID: 38445445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
    Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
    World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.
    Li YA; Zhao C; Ge JJ; Li C; Xue FJ; Qi SP; Zhao C; Kong CC; Zhang JP
    BMC Cancer; 2024 Jun; 24(1):754. PubMed ID: 38907215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficiency of Anlotinib in Patients with Recurrent Grade 4 Glioma: A Single-Center Retrospective Analysis.
    Wang Q; Wei W; Ji X; Li J; Wu N; Li J; Sun K; Ma C; Pan H
    Neurol India; 2024 May; 72(3):578-584. PubMed ID: 39041976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location.
    Guidara S; Seyve A; Poncet D; Leonce C; Bringuier PP; McLeer A; Sturm D; Cartalat S; Picart T; Ferrari A; Hench J; Frank S; Meyronet D; Ducray F; Barritault M
    J Neurooncol; 2024 Sep; 169(2):391-398. PubMed ID: 38937309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
    Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
    CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
    Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 12. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma.
    Park C; Kim TM; Bae JM; Yun H; Kim JW; Choi SH; Lee ST; Lee JH; Park SH; Park CK
    Cancer Res Treat; 2021 Apr; 53(2):389-398. PubMed ID: 33171023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.
    Shen F; Li J; Liu F; Sun N; Qiu X; Ding W; Sun X
    Front Oncol; 2023; 13():1095362. PubMed ID: 36874124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers.
    An T; Hui Q; Zong H; Liu L; Cao X; Li R; Hu S; Liu Y; Li J; Zhao R
    Clin Transl Oncol; 2024 Aug; 26(8):2006-2019. PubMed ID: 38530557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study.
    Yin J; Yin W; Zheng L; Li Y; Luo C; Zhang S; Duan L; Zhou H; Cheng K; Lang J; Xu K
    Clin Med Insights Oncol; 2023; 17():11795549231175714. PubMed ID: 37435019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.
    Yoon HI; Wee CW; Kim YZ; Seo Y; Im JH; Dho YS; Kim KH; Hong JB; Park JS; Choi SH; Kim MS; Moon J; Hwang K; Park JE; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Sung KS; Song JH; Lee MH; Han MH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
    Brain Tumor Res Treat; 2021 Apr; 9(1):1-8. PubMed ID: 33913265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.